Patient focus case studies

Join expert medical oncologist Professor Antonio González-Martín, from the Universidad de Navarra in Spain, in this informative video where he presents a case study of a woman diagnosed with advanced epithelial ovarian cancer. Professor Gonzalez-Martin describes the patient’s medical and family history, clinical presentation and assessments that led to a diagnosis of advanced ovarian cancer.

Part 1: patient case presentation

How would you manage Mayumi? Now that you have watched the patient case presentation, test your knowledge by taking this quiz.

Now that you have taken the quiz, watch this video to find out how Professor González-Martín managed Mayumi, including his recommendations for individualising therapy and the rationale for his choice of treatment for Mayumi.

Part 2: treatment discussion

Patients diagnosed with ovarian cancer should be assessed for BRCA status and after completion of platinum-based chemotherapy^7,8

Meet the expert

Professor Antonio González-Martín MD, PhD

Professor González-Martín is Director of the Medical Oncology Department at Clinica Universidad de Navarra in Madrid, Spain, and Associate Professor of Medicine at Francisco de Vitoria University in Madrid, Spain. Professor González-Martín specializes in the treatment of gynaecological and breast cancer. He is Chairman of GEICO (Spanish Group for Investigation in Ovarian and Gynaecological Cancer) and the GEICO representative in ENGOT (European Network for Gynecological Oncological Trials). Professor González-Martín is a member of the board of the Spanish Society of Medical Oncology (SEOM) and Associate Editor of the International Journal of Gynecological Cancer.

Join oncology expert Professor Em. Ignace Vergote in an interactive patient case study discussion. The patient, Anna, was referred for ultrasound following a period of abdominal discomfort where the specialist discovered she had advanced ovarian cancer. Watch the videos below to learn more about her case and recommended guideline treatment options.

Part 1: patient case presentation

How would you manage Anna? Now that you have watched the patient case presentation, test your knowledge by taking this quiz.

Now that you have taken the quiz, watch this video to find out how Professor Vergote managed Anna, including his recommendations for individualising therapy and the rationale for his choice of treatment.

Part 2: treatment discussion

Meet the expert

Professor Em. Ignace Vergote MD, PhD

Professor Em. Ignace Vergote is professor with scientific assignment at the Catholic University of Leuven and consultant at the University Hospitals Leuven. He specialises in clinical and translational research with a focus on gynaecological cancer. He became Deputy Chairman of the Department of Gynaecologic Oncology at the Norwegian Radium Hospital in 1991, where in initially trained. He is currently Editor of the European Journal of Cancer, the Chair of the Belgian and Luxembourg Gynaecological Oncology Group (BGOG) and has chaired the ENGOT/GOG-Foundation Liaison Committee since 2017. Professor Vergote is Honorary Member of the Finnish Society of Gynaecology and Obstetrics (SGY) the Flemish Society of Obstetrics and Gynaecology and the American College of Surgeons (ACS). 

Join oncology expert Dr Kathleen Moore in this informational patient case study discussion. The patient, Sofia, has a rare, entire BRCA1 gene deletion and a diagnosis of stage IIIC high-grade serous ovarian adenocarcinoma with two recurrences. Watch the videos below to learn more about the role of poly (ADP ribose) polymerase (PARP) inhibitors in recurrent ovarian cancer with germline BRCA gene deletion and the recommended treatment options.

Part 1: patient case presentation

How would you manage Sofia? Now that you have watched the patient case presentation, test your knowledge by taking this quiz.

Now that you have taken the quiz, watch Dr Kathleen Moore explain how Sofia’s cancer was managed, including the various clinical trials supporting the rationale for the selected treatment.

Part 2: treatment discussion

Meet the expert

Dr Kathleen Moore

Dr Kathleen Moore is currently a professor in the Division of Gynecologic Oncology at the University of Oklahoma. She is the Associate Director for Clinical Research and the Director of the Phase I Drug Development Unit at the Stephenson Cancer Center at the University of Oklahoma. She also serves as the medical director for infusion services and is a recent director of the gynecologic oncology fellowship.

Nationally, Dr Moore serves as the NRG Chair for Ovarian Cancer, Associate Director for GOG-Partners and serves on the GOG Foundation Board of Directors. Her interests include drug development and clinical trialist mentorship in gynecologic cancers. She has served as principal investigator for phase 1, 2 and 3 trials including several with registration intent. These include the randomised phase 3 study of olaparib maintenance following response to frontline platinum-based chemotherapy in patients with BRCA mutations ovarian cancer (SOLO-1), the randomised phase 3 trial of mirvetuximab for treatment of platinum-resistant, FRα-high ovarian cancer (MIRASOL) and the randomised phase 3 trial of atezolizumab incorporated into frontline, bevaciziumab containing platinum-based therapy for ovarian cancer (IMagyn050).

Dr Moore has authored over 400 manuscripts, many book chapters, and educational content, and speaks nationally and internationally about gynecologic cancers.